Literature DB >> 2551315

Cytomegalovirus infection in orthotopic liver transplantation.

L H Sayage1, T A Gonwa, R M Goldstein, B S Husberg, G B Klintmalm.   

Abstract

We retrospectively studied 175 orthotopic liver transplants in 151 patients. Of the 151 patients, 59 (39.1%) were diagnosed as having cytomegalovirus (CMV) infection. The rate of infection in patients treated for rejection was 48.8% as compared to 26.2% in patients without rejection (P less than 0.01). Antirejection therapy was associated with culture-positive cases in 33 out of 43 patients as compared to 9 out of 16 patients who had CMV antibody titer elevations. Patients were treated with gancyclovir if they had simultaneous positive cultures from multiple sites and were seriously ill. Eighteen of the 19 patients thus treated had side effects, one of which was serious (bone marrow hypoplasia). Cultures became negative in 15 out of 17 (88%) of the surviving patients. Patient survival was similar to our overall survival rate of 87%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551315      PMCID: PMC7095869          DOI: 10.1007/BF02459327

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  21 in total

1.  DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report.

Authors:  T B Icenogle; E Peterson; G Ray; L Minnich; J G Copeland
Journal:  J Heart Transplant       Date:  1987 Jul-Aug

2.  DHPG (Gancyclovir) improves survival in CMV pneumonia.

Authors:  M Mai; J Nery; W Sutker; B Husberg; G Klintmalm; T Gonwa
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens.

Authors:  C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

4.  Association of renal allograft rejection with virus infections.

Authors:  C Lopez; R L Simmons; S M Mauer; J S Najarian; R A Good; S Gentry
Journal:  Am J Med       Date:  1974-03       Impact factor: 4.965

5.  Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen.

Authors:  C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem.

Authors:  P K Peterson; R Ferguson; D S Fryd; H H Balfour; J Rynasiewicz; R L Simmons
Journal:  Medicine (Baltimore)       Date:  1982-11       Impact factor: 1.889

7.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

8.  Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.

Authors:  E C Reed; R A Bowden; P S Dandliker; K E Lilleby; J D Meyers
Journal:  Ann Intern Med       Date:  1988-11-15       Impact factor: 25.391

9.  Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication.

Authors:  M J Tocci; T J Livelli; H C Perry; C S Crumpacker; A K Field
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

10.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.

Authors:  E C Mar; Y C Cheng; E S Huang
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

View more
  5 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

2.  Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients.

Authors:  X Bai; B B Rogers; P C Harkins; J Sommerauer; R Squires; K Rotondo; A Quan; D B Dawson; R H Scheuermann
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

Review 3.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.

Authors:  M Sakr; T Hassanein; J Gavaler; K Abu-Elmagd; J Fung; R Gordon; T Starzl; D Van Thiel
Journal:  Transplantation       Date:  1992-04       Impact factor: 4.939

Review 5.  Cytomegalovirus infection and disease after liver transplantation. An overview.

Authors:  R J Stratta; M S Shaeffer; R S Markin; R P Wood; A N Langnas; E C Reed; J P Donovan; G L Woods; K A Bradshaw; T J Pillen
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.